Literature DB >> 12644300

Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.

Glendon M Zinser1, Kevin McEleney, JoEllen Welsh.   

Abstract

1,25-Dihydroxyvitamin D(3) (1,25D(3)), the active metabolite of vitamin D(3), inhibits breast cancer cell growth in vivo and in vitro. To examine mechanisms of 1,25D(3) induced growth arrest and apoptosis, cell lines were established from DMBA induced mammary tumors derived from vitamin D(3) receptor knockout (VDRKO) and wild type (WT) mice. Two VDRKO (KO240, KO288) and two WT (WT145, WT276) cell lines were selected and characterized. All four cell lines express cytokeratins indicative of an epithelial origin, as well as vimentin, which is expressed in many transformed cell lines. The tumorigenicity of the cells was confirmed in vivo as all four cell lines form estrogen responsive tumors in nude mice. Both WT cell lines express the VDR protein and are sensitive to growth inhibition by 1,25D(3) at doses as low as 1 nM. Flow cytometric analysis indicated that 1,25D(3) induces G(0)/G(1) arrest and apoptosis in the WT cell lines. In contrast, both cell lines established from tumors that developed in VDRKO mice lack VDR mRNA and protein. Cells from WT mice exhibit 1,25D(3) inducible transcriptional activity, as measured by reporter gene assays, but cells from VDRKO mice do not. Cells from VDRKO mice are also completely resistant to 1,25D(3) mediated growth arrest and apoptosis over the range of 0.01-100 nM 1,25D(3). VDRKO cells are also resistant to the synthetic vitamin D(3) analogs EB1089 and CB1093 that are more potent growth inhibitors than 1,25D(3) in WT cells. This data conclusively demonstrate that the induction of cell cycle arrest and apoptosis in breast cancer cells by 1,25D(3), EB1089 and CB1093 is dependent on the nuclear VDR. Cells lacking VDR remain sensitive to growth arrest mediated by 9-cis retinoic acid, a ligand for the retinoid x receptor which can heterodimerize with the VDR. Sensitivity to apoptosis induced by the DNA damaging agent etoposide is not altered in VDRKO cells, indicating that VDR ablation does not impair apoptotic pathways in general. All four cell lines display equal sensitivity to tamoxifen induced growth arrest. These estrogen responsive, transformed cell lines which differentially express the VDR provide a novel model system for identification of the mechanisms by which 1,25D(3) regulates proliferation and apoptosis in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644300     DOI: 10.1016/s0303-7207(02)00416-1

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  39 in total

1.  Identification of novel mediators of Vitamin D signaling and 1,25(OH)2D3 resistance in mammary cells.

Authors:  Belinda Byrne; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2007-01-24       Impact factor: 4.292

2.  Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study.

Authors:  Lawrence S Engel; Irene Orlow; Camelia S Sima; Jaya Satagopan; Urvi Mujumdar; Pampa Roy; Sarah Yoo; Dale P Sandler; Michael C Alavanja
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-14       Impact factor: 4.254

3.  Synergistic effect and mechanism of vitamin A and vitamin D on inducing apoptosis of prostate cancer cells.

Authors:  Jianjun Sha; Jiahua Pan; Ping Ping; Hanqing Xuan; Dong Li; Juanjie Bo; Dongming Liu; Yiran Huang
Journal:  Mol Biol Rep       Date:  2013-02-23       Impact factor: 2.316

4.  Cell type and gender-dependent differential regulation of the p202 and Aim2 proteins: implications for the regulation of innate immune responses in SLE.

Authors:  Ravichandran Panchanathan; Xin Duan; Muthuvel Arumugam; Hui Shen; Hongzhu Liu; Divaker Choubey
Journal:  Mol Immunol       Date:  2011-09-23       Impact factor: 4.407

5.  CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.

Authors:  Puneet Dhawan; Robert Wieder; Robert Weider; Sylvia Christakos
Journal:  J Biol Chem       Date:  2008-12-03       Impact factor: 5.157

6.  Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.

Authors:  Nair Lopes; Bárbara Sousa; Diana Martins; Madalena Gomes; Daniella Vieira; Luiz A Veronese; Fernanda Milanezi; Joana Paredes; José L Costa; Fernando Schmitt
Journal:  BMC Cancer       Date:  2010-09-11       Impact factor: 4.430

7.  Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells.

Authors:  Jianwei Zhang; Hongyan Zhang; Xia Zhang; Zhonghe Yu
Journal:  Cytotechnology       Date:  2012-10-16       Impact factor: 2.058

Review 8.  Potent 19-norvitamin D analogs for prostate and liver cancer therapy.

Authors:  Atsushi Kittaka; Akihiro Yoshida; Kun-Chun Chiang; Masashi Takano; Daisuke Sawada; Toshiyuki Sakaki; Tai C Chen
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

9.  Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down.

Authors:  José L Costa; Paul P Eijk; Mark A van de Wiel; Derk ten Berge; Fernando Schmitt; Carmen J Narvaez; JoEllen Welsh; Bauke Ylstra
Journal:  BMC Genomics       Date:  2009-10-28       Impact factor: 3.969

10.  Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines.

Authors:  Marcy E Beildeck; Md Islam; Salimuddin Shah; Joellen Welsh; Stephen W Byers
Journal:  PLoS One       Date:  2009-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.